| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Institute of Endocrine Sciences, University of Milan, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena, Via Francesco Sforza 35, 20122 Milan, Italy
1 Pathology Unit, Department of Medicine, Surgery and Dentistry, A O San Paolo, Milan, Italy
2 Department of Neurosurgery, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena, Milan, Italy
3 Endocrine Unit (AP) and Clinical Biochemistry Unit (GM), Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies (DENOThe), University of Florence, Florence, Italy
(Requests for offprints should be addressed to A Spada; Email: anna.spada{at}unimi.it)
Somatostatin analogs currently used in the treatment of acromegaly and other neuroendocrine tumors inhibit hormone secretion and cell proliferation by binding to somatostatin receptor type (SST) 2 and 5. The antiproliferative pathways coupled to these receptors have been only partially characterized. The aim of this study was to evaluate the effect of octreotide and super selective SST2 (BIM23120) and SST5 (BIM23206) analogs on apoptotic activity and apoptotic gene expression in human somatotroph tumor cells. Eight somatotroph tumors expressing similar levels of SST2 and SST5 evaluated by real-time PCR and western blot analyses were included in the study. In cultured cells obtained from these tumors, octreotide induced a dose-dependent increase of caspase-3 activity (160 ± 20% vs basal at 10 nM) and cleaved cytokeratin 18 levels (172 ± 25% vs basal) at concentrations higher than 0.1 nM. This effect was due to SST2 activation since BIM23120 elicited comparable responses, while BIM23206 was ineffective. BIM23120-stimulated apoptosis was dependent on phosphatases, since it was abrogated by the inhibitor orthovanadate, and independent from the induction of apoptosis-related genes, such as p53, p63, p73, Bcl-2, Bax, BID, BIK, TNFSF8, and FADD. In somatotroph tumors, both BIM23120 and BIM2306 caused growth arrest as indicated by the increase in p27 and decrease in cyclin D1 expression. In conclusion, the present study showed that octreotide-induced apoptosis in human somatotroph tumor cells by activating SST2. This effect, together with the cytostatic action exerted by both SST2 and SST5 analogs, might account for the tumor shrinkage observed in acromegalic patients treated with long-acting somatostatin analogs.
This article has been cited by other articles:
|
|
 |
|
  F. Barbieri, A. Pattarozzi, M. Gatti, C. Aiello, A. Quintero, G. Lunardi, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1078 - E1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Acunzo, S. Thirion, C. Roche, A. Saveanu, G. Gunz, A. L. Germanetti, B. Couderc, R. Cohen, D. Figarella-Branger, H. Dufour, et al. Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas Cancer Res., December 15, 2008; 68(24): 10163 - 10170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2 Endocrinology, September 1, 2008; 149(9): 4736 - 4746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Fougner, J. Bollerslev, F. Latif, J. K. Hald, T. Lund, J. Ramm-Pettersen, and J. P. Berg Low Levels of Raf Kinase Inhibitory Protein in Growth Hormone-Secreting Pituitary Adenomas Correlate with Poor Response to Octreotide Treatment J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1211 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Ronchi, E. Rizzo, A. G Lania, R. Pivonello, S. Grottoli, A. Colao, E. Ghigo, A. Spada, M. Arosio, and P. Beck-Peccoz Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal Eur. J. Endocrinol., January 1, 2008; 158(1): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Zatelli, M. R. Ambrosio, M. Bondanelli, and E. C d. Uberti Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S29 - S35. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
